Shanxi C&Y Pharmaceutical Group Co Ltd (300254) — Strategic Asset Allocation Index
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Strategic Asset Allocation Index of 47.8% as of June 2023. Strategic assets (PP&E of CN¥340.26 Million plus long-term investments of CN¥-) total CN¥340.26 Million, measured against net assets of CN¥711.91 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check how resilient are Shanxi C&Y Pharmaceutical Group Co Ltd's assets to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
Shanxi C&Y Pharmaceutical Group Co Ltd Strategic Asset Allocation Index (2008–2021)
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Strategic Asset Allocation Index has evolved across 14 annual periods from 2008 to 2021. As of June 2023, the index stands at 47.8%, representing strategic assets of CN¥340.26 Million against net assets of CN¥711.91 Million CNY. See Shanxi C&Y Pharmaceutical Group Co Ltd free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2021, covering 14 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Shanxi C&Y Pharmaceutical Group Co Ltd market cap and net worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 51.9% | CN¥386.14 Million | CN¥386.14 Million | CN¥- | CN¥744.58 Million | ▲ +6.2 pp |
| 2020 | 45.7% | CN¥398.68 Million | CN¥398.68 Million | CN¥- | CN¥872.61 Million | ▲ +6.7 pp |
| 2019 | 39.0% | CN¥363.83 Million | CN¥363.83 Million | CN¥- | CN¥932.60 Million | ▼ -11.4 pp |
| 2018 | 50.4% | CN¥469.47 Million | CN¥389.69 Million | CN¥79.78 Million | CN¥931.24 Million | ▲ +1.0 pp |
| 2017 | 49.4% | CN¥480.04 Million | CN¥397.40 Million | CN¥82.65 Million | CN¥971.17 Million | ▲ +2.6 pp |
| 2016 | 46.8% | CN¥447.21 Million | CN¥353.84 Million | CN¥93.38 Million | CN¥954.85 Million | ▲ +0.3 pp |
| 2015 | 46.5% | CN¥406.12 Million | CN¥347.79 Million | CN¥58.33 Million | CN¥872.50 Million | ▲ +2.3 pp |
| 2014 | 44.2% | CN¥364.04 Million | CN¥364.04 Million | CN¥- | CN¥823.16 Million | ▼ -20.6 pp |
| 2013 | 64.8% | CN¥497.33 Million | CN¥497.33 Million | CN¥- | CN¥767.16 Million | ▲ +38.5 pp |
| 2012 | 26.4% | CN¥171.66 Million | CN¥171.66 Million | CN¥- | CN¥651.17 Million | ▲ +2.7 pp |
| 2011 | 23.6% | CN¥137.41 Million | CN¥137.41 Million | CN¥- | CN¥581.17 Million | ▼ -48.7 pp |
| 2010 | 72.3% | CN¥108.18 Million | CN¥108.18 Million | CN¥- | CN¥149.59 Million | ▲ +13.7 pp |
| 2009 | 58.6% | CN¥68.95 Million | CN¥68.95 Million | CN¥- | CN¥117.60 Million | ▼ -10.3 pp |
| 2008 | 68.9% | CN¥73.51 Million | CN¥73.51 Million | CN¥- | CN¥106.70 Million | — |